Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135448 | 1.00 | CHRM2 (0.66) | CHRM2CHRM1CHRM3PREPDPP4 | |
| SCHEMBL796116 | 1.00 | CHRM2 (0.66) | CHRM2CHRM1CHRM3PREPDPP4 | |
| SCHEMBL16116400 | 1.00 | CHRM2 (0.66) | CHRM2CHRM1CHRM3PREPDPP4 | |
| Potassium Ion SCHEMBL30567066 | 0.94 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPDPP4 | |
| SCHEMBL26922641 | 0.92 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPDPP4 | |
| SCHEMBL23417285 | 0.84 | CHRM2 (0.71) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25881058 | 0.84 | CHRM2 (0.71) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL31398492 | 0.82 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPDPP4 | |
| SCHEMBL2123260 | 0.80 | CHRM2 (0.75) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25010681 | 0.80 | CHRM2 (0.75) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4499634-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4482587-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20160214974-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-07-28 | — | — | US | disclosed |
| EP-3041833-A1 | INSECTICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016050567-A1 | INSECTICIDAL CYANOTROPANE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-04-07 | — | — | WO | disclosed |
| US-20160050930-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (UK) | 2016-02-25 | — | — | US | disclosed |
| US-20160050929-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-25 | — | — | US | disclosed |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2978316-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | Syngenta Participations AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| WO-2015032617-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014154488-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | CHRM2 4816/4885CHRM1 4866/4885CHRM3 4862/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | CHRM2 4884/4885CHRM1 4874/4885CHRM3 4873/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | CHRM2 4831/4885CHRM1 4862/4885CHRM3 4819/4885 |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | CHRM2 4503/4885CHRM1 4659/4885CHRM3 4670/4885 |
| US-20160214974-A1 | INSECTICIDAL COMPOUNDS | ACHE, CYP1B1, CHRM1 | CHRM2 15/4885CHRM1 3/4885CHRM3 37/4885 |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | CRY1, DDT, CYC1 | CHRM2 113/4885CHRM1 139/4885CHRM3 296/4885 |
| US-20160050929-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | DDT, CRY1, NISCH | CHRM2 59/4885CHRM1 162/4885CHRM3 255/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | CHRM2 4831/4885CHRM1 4862/4885CHRM3 4819/4885 |
| US-20160050930-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | DDT, CRY1, NISCH | CHRM2 50/4885CHRM1 111/4885CHRM3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.